Summary
A study has been in progress since June 1985 to evaluate the use of myeloablative therapy (cyclophosphamide [60 mg/kg × 21 and total body irradiation [200 cGy × 6]) followed by reinfusion of autologous bone marrow in patients in second or subsequent remission of B-cell non-Hodgkin’s lymphoma. The marrow mononuclear cell fraction is being treated in vitro with three cycles of the monoclonal antibody anti-CD20 (anti-B1, Coulter Immunology) and baby rabbit complement (Pel-Freez).
Thirty-eight patients with follicular lymphoma (age range 29–61 years, median 43) have been treated to date. At the time of treatment, 28 patients were in second remission, 7 were in third, and 3 were in more than third remission. Twenty-three patients were in complete remission, 15 had residual disease (7 had lymph nodes < 2 cm diameter, 4 had < 10% bone marrow infiltration, 1 had involvement of lymph nodes and bone marrow, and 3 had involvement at other sites). Of the 38 study patients, 32 are alive; 6 have died, 4 in remission. Two of the deaths were treatment related: 1 resulted from cerebral haemorrhage at 29 days; 1 resulted from systemic fungal infection at three months). One patient died from secondary acute myelogenous leukaemia at four years, and another from an unrelated cause. Two patients died following relapse. The median time to engraftment was 28 days (range 15–45 days) for neutrophils > 0.5 × 109/L and 28 days (range 15–46 days) for platelets > 20 × 109/L.
Twenty-six patients continue in remission between one month and five years (median follow-up 22 months); 8 have relapsed, 2 with transformation to high-grade histology. In the context of the natural history of follicular lymphoma these results are preliminary but encouraging. It remains to be established whether such intensive therapy is curative.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kennedy T et al. Combination vs successive single agent chemotherapy in lymphocytic lymphoma. Cancer 1978; 41: 23.
Lister TA et al. Comparison of combined and single agent chemotherapy in non-Hodgkin’s lymphoma of favourable histological type. Br Med J 1978; 1: 533.
Hoppe RT, Kushalan P, Kaplan HS et al. The treatment of advanced stage favourable histology non-Hodgkin’s lymphoma: A preliminary report of a randomised trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation. Blood 1981; 58: 592.
Gallagher CJ et al. Follicular Lymphoma: Prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470.
Armitage JO, Gingrich RD, Klassen LW et al. Trial of high dose Cytarabine, Cyclophosphamide, total body irradiation and autologous bone marrow transplantation for refractory lymphoma. Cancer Treat Rep 1986; 70: 871.
Philip T, Armitage JO, Spitzer G et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non-Hodgkin’s lymphoma. N Engl J Med 1987; 316: 1493.
Gulati SC, Shank B, Black P et al. Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J Clin Oncol 1988; 1303.
Goldstone AH, Linch DC, Gribben JG et al. Experience of autologous bone marrow transplantation in the first 100 lymphomas. Bone Marrow Transplant 1988; 3: 65.
Colombat P, Gorin NC, Lemonnier MP et al. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin’s lymphoma. J Clin Oncol 1990; 8 (4): 630.
Petersen FB, Appelbaum FR, Hill R et al. Autologous transplantation for malignant lymphoma: A report of 101 cases from Seattle. J Clin Oncol 1990; 8 (4): 638.
Freedman AS, Takvorian T, Anderson KC et al. Autologous bone marrow transplantation in B cell non-Hodgkin’s lymphoma: very low treatment mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; (in press).
Young RC, Longo DL, Glatstein E et al. The treatment of indolent lymphomas; watchful waiting vs aggressive combined modality treatment. Sem Hem 1988; 25 (2): 11.
McLaughlin P, Fuller L, Velasquez W et al. Stage III Follicular Lymphoma: durable remissions with combined chemotherapy and radiotherapy regime. J Clin Oncol 1987; 5: 867.
Peterson BA, Anderson JR, Frizzera CD et al. Combination chemotherapy prolongs survival in follicular mixed lymphoma (FML). Proc ASCO 1990; 9: 259.
Nadler LM, Takvorian T, Botnick L et al. Anti-B1 monoclonal antibody and complement treatment in autologous bone marrow transplantation for relapsed B cell non-Hodgkin’s lymphoma. Lancet 1984; 2: 427.
Dorey EL, Outram SV, Holder A et al. Assessment of bone marrow infiltration in B cell non-Hodgkin’s lymphoma. Br J Cancer 1989; 59: 772.
Storring RA, McElwain TJ, Jameson B et al. Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia. Lancet 1977; ii: 837.
Anderson KC, Ritz J et al. Haematologic engraftment and immune reconstitution post-transplantation with anti-B1 purged autologous bone marrow. Blood 1987; 69: 597.
Price CGA, Rohatiner AZS, Cotter FE et al Minimal residual disease and the efficacy of in vitro bone marrow (BM) purging in follicular lymphoma measured by an adapted polymerase chain reaction technique. Proc ASCO 1990; 9: 258.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Rohatiner, A.Z.S. et al. (1991). Myeloablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. In: Ultmann, J.E., Samuels, B.L. (eds) Annals of Oncology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7305-4_23
Download citation
DOI: https://doi.org/10.1007/978-1-4899-7305-4_23
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-7294-1
Online ISBN: 978-1-4899-7305-4
eBook Packages: Springer Book Archive